Eugia Pharma announces launch of Pomalidomide Capsules in the US

Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market.

The product is the generic equivalent of Pomalyst® Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp. Eugia Pharma Specialities Limited was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I.

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.

Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1211.35 as compared to the previous close of Rs. 1221.55. The total number of shares traded during the day was 43111 in over 3916 trades.

The stock hit an intraday high of Rs. 1223.25 and intraday low of 1180.05. The net turnover during the day was Rs. 52138046.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals EugiaPharmaSpecialities PomalidomideCapsules